treatment for COVID-19 – Page 26 – Communicable Diseases Research

Genome sequencing and the diagnosis of novel coronavirus (SARS-COV-2) in Africa: how far are we?

Review

Published on 2020-06-092022-10-28
Journal: The Pan African Medical Journal
[Category] COVID-19, MERS, SARS,

A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol

Letter

Published on 2020-06-082022-10-29
Journal: Trials
[Category] COVID-19, SARS,

[키워드] 1:1 24 hour 28-day mortality activated acute respiratory distress syndrome Administered Admission adverse effect age albumin allergic allocation concealment Anticoagulant apheresis approval approved assessment Basel block size C-reactive protein category changes in city Coagulopathy Control COVID-19 COVID-19 disease criteria Cytokine release syndrome D-dimer defined disease dissemination drug eight element Enrollment evaluate evaluated ferritin fibrinogen first dose FIVE food function group ICU ICU admission ill patient Improving Inc. Inflammatory ingredient intensive care intensive care unit International Intervention intervention group intubation IRB ISRCTN KDIGO King Kingdom Laboratory lack lactate dehydrogenase life threatening life-threatening Life-threatening COVID-19 marker measure Mild Ministry of Health Multicenter trial Multisystem organ failure National negative RT-PCR normalized number objective occur on mechanical ventilation Open-label outcome Palliative care participant Participants Patient patients performed pilot study plasma primary site Prothrombin time protocol Qiagen randomization randomize Randomized Randomized controlled trial randomized trial Real-time PCR receive receiving recommendations recruit reduce replaced Roche RT-PCR RT-PCR kit Safety Sample size SARS CoV-2 SARS-CoV-2 SARS-COV-2 infection Saudi Arabia secondary serum Seven sodium SOFA status Stratification Study protocol supportive care Switzerland System Therapeutic plasma exchange therapy TPE treatment for COVID-19 tumor necrosis factor-alpha USA Volume website
[DOI] 10.1186/s13063-020-04454-4 PMC 바로가기 [Article Type] Letter

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-06-082022-10-29
Journal: Trials
[Category] COVID-19, SARS,

[키워드] activity adverse event allergic reaction anti-SARS-CoV-2 anti-SARS-CoV-2 antibody Anti-SARS-CoV-2 plasma Anti-viral blinded Blood blood product center Chest radiography Clinical improvement Clinical outcome clinical status clinical trial clinician collected Columbia University control arm convalescent plasma coronavirus COVID-19 COVID-19 symptom criteria cumulative Date defined Dilution discharge dissemination Donor ECMO Efficacy Efficacy and safety element evaluate Evaluating Evidence extracorporeal membrane oxygenation hazard hazard ratio HBV HCV HIV hospital Hospitalized hospitalized patient IgA deficiency immune incidence include Infection Influenza Invasive mechanical ventilation mechanical ventilation multi-organ failure nasopharyngeal Nasopharyngeal swab New York Non-invasive number objective occur oropharyngeal swab outcome oxygen saturation participant Participants patients hospitalized PCR test PCR-negative per-protocol analysis peripheral capillary plasma platform post-hoc analysis Pregnancy primary endpoint protocol randomization Randomized Randomized controlled trial randomized, controlled trial randomly permuted block receive Registered Remdesivir requiring high-flow oxygen requiring supplemental oxygen Research Respiratory failure retrospective Ritonavir safety endpoint Sample size SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection screened Serious Adverse Event seven-point ordinal scale severe COVID-19 severe SARS-CoV-2 severely ill adult single-center spike trimer SpO2 status study participant study period Study protocol supplemental oxygen tested therapy transfused Treatment treatment for COVID-19 Trial undergo USA Version Volunteer Wald test website with COVID-19 World Health Organization ZIKV
[DOI] 10.1186/s13063-020-04422-y PMC 바로가기 [Article Type] Letter

The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials
[Category] Coronavirus, SARS,

[키워드] 24 hours acid Administered Affect analyst Anti-viral anticipated Beijing block block randomization Blood Body Capital cardiovascular system Care center changed Chinese clinical clinical manifestation Clinical outcome Clinical studies clinical trial college Complete condition Consent control group Corona Corona virus cough COVID-19 criteria curative Diagnosis discharge discharged disease Diseases dissemination dose drug Ebola virus element eligibility criteria enrolled expected experimental group Favipiravir female Follow-up form hepatology history hospital include Including Infection Infectious disease Informed inhibit investigators kidney lack lactating women life-threatening liver Loss male Measures mechanism Medicine Mental Disorders Nasopharyngeal swab nasopharyngeal swabs not blinded nucleic acid nucleic acid test number objective open label oral administration outcome outcome assessors Oxygen therapy parallel group participant Participants Patient plan poor compliance positive protocol Public pulmonary randomised randomised controlled trial randomization system Randomized controlled trial Randomly recruited recruitment reduced Regular Reinfection Research researcher respiratory specimen response returned RNA-dependent RNA polymerase routine screening visit second secondary severe adverse events severity severity of symptoms Shenzhen specimens sputum status Study protocol subject Symptom Symptoms System temperature Test tested therapeutic efficacy throat swabs Traditional Treatment treatment for COVID-19 treatment group Trial uncontrolled university variety viral nucleic acid virus Web website Withdrawal Wuhan
[DOI] 10.1186/s13063-020-04430-y PMC 바로가기 [Article Type] Letter

Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable

Editorial

Published on 2020-06-012022-10-05
Journal: Radiotherapy and oncology : journal of the Europea
[Category] 임상,

[키워드] clinical trial Pneumonia radiation therapy risk treatment for COVID-19
[DOI] 10.1016/j.radonc.2020.04.060 [Article Type] Editorial

Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia

Case Reports

Published on 2020-05-272022-10-06
Journal: Stem Cell Research & Therapy
[Category] MERS, SARS, 진단,

[키워드] C-reactive protein CD3 CD4 CD8 China COVID-19 COVID-19 pathogenesis discharged drug effective global public health healthy donor highlight Human umbilical cord Wharton’s jelly-derived MSCs IL-6 immune system immunomodulatory Infection Inflammation intravenous intravenous infusion Liaocheng Lymphocyte subset mesenchymal stem cell MSC MSCs novel coronavirus disease Patient patients with COVID-19 Pneumonia Potential treatment Pulmonary function Safe severe COVID-19 shown significantly stem cell Symptom T cell the patient TNF-α treated Treatment treatment for COVID-19 umbilical Vaccine Wharton’s jelly-derived MSC with COVID-19 Wuhan, China
[DOI] 10.1186/s13287-020-01725-4 PMC 바로가기 [Article Type] Case Reports

Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections

Bioengineering and Biotechnology

Published on 2020-05-262022-10-31
Journal: Frontiers in Bioengineering and Biotechnology
[Category] COVID-19,

[키워드] Administered Advancing anti-inflammatory agents Anti-viral attenuate Beat Can caused clinical trial clinical utility Combination coronavirus (2019-nCoV) COVID-19 COVID-19 disease curative Cytokine storm disease EVs Exosome extracellular vesicle Extracellular vesicles immunomodulatory IMPROVE Inflammation intravenously investigated lung damage lung injuries mainstream majority mechanism Medicine MSC MSCs outcome Patient people with COVID-19 pharmacological treatments regenerative properties reported risk SARS-CoV-2 SARS-CoV-2 virus secreted STEM stem cell Stem cell therapy survival therapeutic agents therapeutic effect therapeutic potential therapeutic strategy Therapies therapy Treatment treatment for COVID-19 Trial while
[DOI] 10.3389/fbioe.2020.00554 PMC 바로가기 [Article Type] Bioengineering and Biotechnology

Minimum costs to manufacture new treatments for COVID-19

Research article

Published on 2020-04-012022-10-05
Journal: Journal of Virus Eradication
[Category] 신약개발, 치료법,